Today: 28 June 2026
Browse Category

NASDAQ:GOSS 24 February 2026

Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story

Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story

Gossamer Bio shares traded near $0.42 in early premarket Tuesday after plunging about 80% when its main drug failed to meet the primary goal in a Phase 3 trial. The company said the study’s key endpoint improved by 13.3 meters but did not reach statistical significance. Analysts downgraded the stock and flagged risks around funding and regulatory timelines. Gossamer plans to meet the FDA and paused another study.
24 February 2026
···

Stock Market Today

  • Goldman Sachs Shares Pull Back 7% After 50% Annual Gain; Valuation Seen Slightly Overvalued
    June 28, 2026, 4:22 AM EDT. Goldman Sachs (GS) shares closed at $1,019.61 on June 28, down 7% over the past week but up 50.6% over the last year. Despite a strong three-year gain of 239.1%, the stock showed a recent pullback. Valuation analysis using an Excess Returns model indicates the stock is about 10.4% overvalued, with an intrinsic value estimated at $923.45 versus the current price. Investors are advised to carefully consider Price-to-Earnings (P/E) ratios and valuation models amid robust long-term gains and evolving market conditions before making new investment decisions.

Latest articles

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 28.06.2026

28 June 2026
LIVEMarkets rolling coverageStarted: June 28, 2026, 4:00 AM EDTUpdated: June 28, 2026, 4:28 AM EDT Goldman Sachs Shares Pull Back 7% After 50% Annual Gain; Valuation Seen Slightly Overvalued June 28, 2026, 4:22 AM EDT. Goldman Sachs (GS) shares closed at $1,019.61 on June 28, down 7% over the past week but up 50.6% over the last year. Despite a strong three-year gain of 239.1%, the stock showed a recent pullback. Valuation analysis using an Excess Returns model indicates the stock is about 10.4% overvalued, with an intrinsic value estimated at $923.45 versus the current price. Investors are advised to
Go toTop